Interpace Biosciences, Inc. (IDXG)
6.20
+0.15
(+2.48%)
USD |
OTCM |
Nov 16, 16:00
Interpace Biosciences Enterprise Value : 32.64M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | 32.64M |
| November 13, 2026 | 31.80M |
| November 12, 2026 | 32.64M |
| November 11, 2026 | 34.85M |
| November 10, 2026 | 37.07M |
| November 09, 2026 | 37.07M |
| November 06, 2026 | 37.07M |
| November 05, 2026 | 37.07M |
| November 04, 2026 | 29.98M |
| November 03, 2026 | 28.44M |
| November 02, 2026 | 28.44M |
| October 30, 2026 | 29.27M |
| October 29, 2026 | 29.98M |
| October 28, 2026 | 25.71M |
| October 27, 2026 | 28.76M |
| October 26, 2026 | 28.76M |
| October 23, 2026 | 34.30M |
| October 22, 2026 | 28.20M |
| October 21, 2026 | 26.26M |
| October 20, 2026 | 27.65M |
| October 19, 2026 | 25.99M |
| October 16, 2026 | 26.82M |
| October 15, 2026 | 27.48M |
| October 14, 2026 | 28.86M |
| October 13, 2026 | 30.97M |
| Date | Value |
|---|---|
| October 12, 2026 | 32.25M |
| October 09, 2026 | 31.53M |
| October 08, 2026 | 31.53M |
| October 07, 2026 | 31.53M |
| October 06, 2026 | 31.67M |
| October 05, 2026 | 31.67M |
| October 02, 2026 | 31.67M |
| October 01, 2026 | 33.69M |
| September 30, 2026 | 33.69M |
| September 29, 2026 | 33.85M |
| September 28, 2026 | 33.85M |
| September 25, 2026 | 33.80M |
| September 23, 2026 | 34.13M |
| September 22, 2026 | 34.13M |
| September 21, 2026 | 34.02M |
| September 18, 2026 | 34.02M |
| September 17, 2026 | 34.02M |
| September 16, 2026 | 34.02M |
| September 15, 2026 | 34.30M |
| September 14, 2026 | 33.19M |
| September 11, 2026 | 34.30M |
| September 10, 2026 | 34.69M |
| September 09, 2026 | 34.30M |
| September 08, 2026 | 36.58M |
| September 04, 2026 | 36.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Exlites Holdings International, Inc. | 15.42M |
| Xcelerate, Inc. | 11.11M |
| Vivos Therapeutics, Inc. | 12.86M |
| Hinge Health, Inc. | 9.590B |
| PD-Rx Pharmaceuticals, Inc. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.266M |
| Revenue (Quarterly) | 9.131M |
| Total Expenses (Quarterly) | 8.865M |
| EPS Diluted (Quarterly) | 0.0285 |
| Gross Profit Margin (Quarterly) | 61.91% |
| Profit Margin (Quarterly) | 2.91% |
| Earnings Yield | 71.16% |
| Operating Earnings Yield | 12.13% |
| Normalized Earnings Yield | 70.92 |